TGCT CAN WRECK YOUR PATIENT’S JOINT

TGCT CAN

WRECK YOUR

PATIENT’S JOINT

Tenosynovial giant cell tumor (TGCT) is a non-malignant but locally aggressive disease that can cause severe disability and permanent destruction to the joint.¹ The pain, swelling, and stiffness associated with TGCT can severely impact patients’ work, family life, and social activities.²

LEARN MORE

The latest information about TGCT

Progressive and multifaceted patient burden

Learn more about the physical, mental, and occupational impacts of TGCT for patients.

Explore The BURDEN OF TGCT

Evolving consensus on TGCT and its managemant

Evolving consensus on TGCT and its management

Consider some of the latest thinking about TGCT diagnosis and management.

See The Latest Developments

The current treatment landscape

Take a closer look at different approaches to treatment for TGCT.

See The Options

SIGN UP FOR MORE INFORMATION ABOUT TGCT

Get the latest updates from EMD Serono

STAY INFORMED

REFERENCES

1. Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. doi:10.1016/j.ctrv.2022.102491 2. Stern S, McKenzie PF, Bernthal N, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510. doi:10.1080/14796694.2025.2488635

EMD Serono is a Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.

200 Pier 4 Blvd, Boston, MA 02210

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

US-NONOTGCT-00007 10/25